{"product_id":"understanding-molecular-diagnostics-in-thyroid-pathology-a-patients-guide-to-genetic-testing-for-thyroid-nodules","title":"Understanding Molecular Diagnostics in Thyroid Pathology: A Patient's Guide to Genetic Testing for Thyroid Nodules","description":"\u003cp\u003eThyroid nodules are extremely common, and while most are benign, determining which ones are cancerous can be challenging. This review article explains how molecular diagnostic testing—which analyzes the genetic makeup of cells from a biopsy—has revolutionized the way doctors evaluate and manage thyroid nodules, particularly those with \"indeterminate\" results that are neither clearly benign nor clearly malignant. The authors trace the evolution of these tests from early single-gene analysis to today's sophisticated panels that can detect hundreds of genetic mutations and fusions, and they explain how this information helps doctors make better decisions about surgery, monitoring, and targeted treatment. For patients, this means fewer unnecessary surgeries, more precise risk assessment, and access to personalized therapies for advanced or aggressive thyroid cancers.\u003c\/p\u003e\n\n\u003ch1\u003eUnderstanding Molecular Diagnostics in Thyroid Pathology: A Patient's Guide to Genetic Testing for Thyroid Nodules\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Why This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#history\"\u003eThe History of Molecular Testing in Thyroid Diagnostics\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#fna\"\u003eFine Needle Aspiration and the Emergence of Molecular Testing Platforms\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#clinical\"\u003eMolecular Tests in Clinical Practice: How Testing Works\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#itn\"\u003eMolecular Tests for Indeterminate Thyroid Nodules\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eClinical Implications: What This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations of the Study\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eMolecular testing helps classify indeterminate thyroid nodules, reducing unnecessary surgeries.\u003c\/li\u003e\n\u003cli\u003eMain platforms: Afirma GSC\/XA, ThyroSeq v3, and ThyGeNEXT\/ThyraMIR.\u003c\/li\u003e\n\u003cli\u003eBenign results may allow active surveillance instead of surgery.\u003c\/li\u003e\n\u003cli\u003eSuspicious results, especially with BRAF or TERT mutations, may prompt surgery.\u003c\/li\u003e\n\u003cli\u003eFor advanced cancer, testing identifies targeted therapy options like RET or NTRK inhibitors.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: Why This Research Matters\u003c\/h2\u003e\n\n\u003cp\u003eThyroid nodules—lumps that form in the thyroid gland at the base of the neck—are remarkably common. The challenge for doctors is determining which nodules are harmless and which are cancerous. This is no small task, as the evaluation process involves multiple steps including blood tests, imaging studies, and sometimes tissue sampling.\u003c\/p\u003e\n\n\u003cp\u003eFor nodules that raise concern about cancer, fine needle aspiration biopsy (FNAB) is considered the gold standard for evaluation. During this procedure, a thin needle is inserted into the nodule to collect cells for examination under a microscope. However, in up to 30% of cases, the results come back \"indeterminate\"—meaning the cells look abnormal but doctors cannot definitively say whether they are benign or malignant. This creates a clinical dilemma: should the patient undergo surgery to remove the nodule, or can it be safely monitored?\u003c\/p\u003e\n\n\u003cp\u003eThis is where molecular testing has become a game-changer. Advances in our understanding of the genetic underpinnings of thyroid cancer have led to the development of tests that can analyze the DNA and RNA of cells from biopsy samples. These tests help doctors classify indeterminate nodules more accurately, predict how aggressive a cancer might be, and even guide treatment decisions for advanced disease.\u003c\/p\u003e\n\n\u003cp\u003eThe authors of this review, Drs. Bayan Alzumaili and Peter M. Sadow from Massachusetts General Hospital and Harvard Medical School, provide a comprehensive update on the evolution of molecular diagnostics in thyroid pathology. They explain how our growing knowledge of tumor genetics, combined with traditional histopathology (the microscopic examination of tissue), is driving the next generation of rational patient management—particularly in the context of emerging small, targetable therapeutics.\u003c\/p\u003e\n\n\u003cp\u003eOne landmark development was the publication of The Cancer Genome Atlas (TCGA) consortium's molecular landscape of papillary thyroid carcinoma (PTC) in 2014. This work dramatically reduced the \"black matter\"—the unknown genetic drivers—in PTC from 25% to just 3.5%. The TCGA classified tumors into two main categories: BRAF V600E-like and RAS-like phenotypes. Subsequent research by Yoo and colleagues described the mutational landscape in follicular thyroid adenomas (FTA) and follicular thyroid carcinomas (FTC), adding a third category: Non-BRAF\/Non-RAS (NBNR) tumors that behaved in an intermediate fashion. This NBNR group included genetic fusion events involving tyrosine kinases such as RET, NTRK, ALK, and ROS.\u003c\/p\u003e\n\n\u003ch2 id=\"history\"\u003eThe History of Molecular Testing in Thyroid Diagnostics\u003c\/h2\u003e\n\n\u003cp\u003eThe journey toward today's sophisticated molecular tests began decades ago. In the 1960s, Lindsay and colleagues first described the nuclear features of papillary thyroid carcinoma. A decade later, Chen and Rosai described the follicular variant of PTC (FVPTC). These early descriptions were purely based on microscopic appearance—no one yet knew about the genetic drivers behind these cancers.\u003c\/p\u003e\n\n\u003cp\u003eThe first genetic discoveries came in 1987 when Fusco and colleagues identified TRK and RET rearrangements in five papillary thyroid carcinomas and their metastatic lymph nodes. This groundbreaking work inspired Santoro and colleagues to conduct a larger study on 286 thyroid tumors, including 177 PTCs, 37 FTCs, 15 anaplastic thyroid carcinomas (ATCs), 18 medullary thyroid carcinomas (MTCs), 34 benign thyroid nodules, and 5 cases of squamous cell carcinoma and sarcomatoid carcinoma. They found RET aberrations exclusively in 19% of PTCs (33 out of 177 cases).\u003c\/p\u003e\n\n\u003cp\u003eIn 1989, Lemoine and colleagues identified NRAS p.Q61R and HRAS p.Q61R mutations across all stages of the thyroid neoplastic process—from benign follicular adenomas to follicular carcinomas and anaplastic thyroid carcinomas. Namba and colleagues then found further genetic variants within RAS subtypes (NRAS, HRAS, and KRAS) at codons 12 and 13 in both benign and neoplastic thyroid nodules.\u003c\/p\u003e\n\n\u003cp\u003eThe year 2000 brought another important discovery when Kroll and colleagues reported the PAX8::PPARG fusion in five of eight follicular thyroid carcinomas but not in 20 follicular adenomas, 10 PTCs, or 10 multinodular hyperplasias. Nikiforova and colleagues later found the same fusion event in 8 of 15 (53%) FTCs and 2 of 25 (8%) FTAs, but not in 35 PTCs (including 12 follicular variants), 12 oncocytic thyroid carcinomas, 12 oncocytic thyroid adenomas, 2 ATCs, 1 poorly differentiated thyroid carcinoma, or 16 hyperplastic nodules.\u003c\/p\u003e\n\n\u003cp\u003eAt the turn of the twenty-first century, two distinct pathways were emerging in thyroid tumorigenesis. One was RAS-associated or PAX8::PPARG-related with a predominant follicular growth pattern. The other was not fully explained by RET or TRK aberrations. The inverse association between BRAF and RAS in alternative activation of MEK\/MAPK signaling in many tumors—including colon and ovarian tumors—inspired Cohen and colleagues to explore the role of BRAF in predominantly RAS-negative PTC. Their work identified BRAF p.T1796A in 69% of PTCs (24 of 35 cases).\u003c\/p\u003e\n\n\u003cp\u003eOf brief note, the original nomenclature referred to the nucleotide rather than the codon. The erroneous BRAF T1796A (then called BRAF p.V599E) eventually came to be recognized as BRAF T1799A (now known as BRAF p.V600E) after the error was realized. Since then, molecular studies have progressed to become a standard and integral part of our understanding of thyroid tumorigenesis and biological potential.\u003c\/p\u003e\n\n\u003ch2 id=\"fna\"\u003eFine Needle Aspiration and the Emergence of Molecular Testing Platforms\u003c\/h2\u003e\n\n\u003cp\u003eFine needle aspiration biopsy with cytological evaluation remains the most reliable and commonly used tool for cancer diagnosis in thyroid nodules. The arrival of preoperative ancillary molecular diagnostics for nodules of indeterminate cytology was field-changing for the past decade.\u003c\/p\u003e\n\n\u003cp\u003ePrior to molecular platforms for FNAB material, individual gene testing was more common in surgical resections. These tests were more expensive, assayed far fewer genes, and worked with less reliable, longer genetic primers. In 2009, Nikiforov and colleagues conducted a pivotal study on FNAB samples from thyroid nodules with Bethesda categories of benign, indeterminate, and malignant. Their group analyzed BRAF variants (p.V600E, p.K601E), NRAS, KRAS, and HRAS along with genetic fusion products RET::PTC1 (CCDC6::RET), RET::PTC3 (NCOA4::RET), and PAX8::PPARG—genetic changes commonly associated with thyroid neoplasia.\u003c\/p\u003e\n\n\u003cp\u003eBiopsies positive for genetic aberrations were nearly uniformly found to be malignant following surgical excision. These results have been clarified over the years with broader panels, larger cohorts, and refined diagnostic criteria for malignancy. This discovery has greatly improved preoperative diagnosis for indeterminate thyroid nodules, confirming neoplasia and providing increasing granularity around risk of malignancy.\u003c\/p\u003e\n\n\u003cp\u003eIn 2012, Alexander and colleagues conducted a prospective, multicenter validation study of 577 indeterminate thyroid nodules, 413 of which had corresponding histopathological specimens. Using machine learning to interpret mRNA expression of 167 genes through microarray platforms, the Afirma Gene Expression Classifier (GEC) studied indeterminate nodules and correctly identified 78 of the 85 excised malignant nodules as suspicious. This yielded a sensitivity of 92% and a specificity of 52%. The study aimed to eliminate unnecessary thyroid surgeries by ruling out thyroid neoplasms and recommended a conservative approach for most patients with indeterminate nodules and benign results according to GEC. Afirma GEC was the first rule-out test for thyroid neoplasms.\u003c\/p\u003e\n\n\u003cp\u003eIn 2018, the Afirma Genomic Sequencing Classifier (GSC) was developed to better describe the RNA transcriptome with additional sequencing of nuclear and mitochondrial genes and genomic copy number changes, including loss of heterozygosity. This resulted in a more robust genomic test. For indeterminate nodules with non-oncocytic histology, the sensitivity was 92% and the specificity was 70%.\u003c\/p\u003e\n\n\u003cp\u003eAlthough Afirma GEC was highly sensitive, certain thyroid tumors—like oncocytic neoplasms—were intentionally called suspicious, resulting in lower specificity for such neoplasms. With the improved GSC, Hao and colleagues used next-generation sequencing of whole transcriptome RNA sequencing in FNA nodules with oncocytic features to identify mitochondrial and nuclear expression of genes related to oncocytic (formerly Hürthle cell) neoplasms. The specificity of this algorithmic classification increased dramatically from 12% to 59%.\u003c\/p\u003e\n\n\u003cp\u003eIn 2013, the first version of the targeted next-generation sequencing panel ThyroSeq was published. ThyroSeq used NGS platforms for 12 genes to include 284 hot spot mutations, covering more than 95% of the reported variants in genes associated with thyroid neoplasms. In addition to some mutations detected by GEC (BRAF, RET, NRAS, KRAS, and HRAS), ThyroSeq studied PIK3CA, TP53, TSHR, PTEN, GNAS, CTNNB1, and AKT1. Notably, PAX8::PPARG fusion and RET- and TRK-rearranged genes were not included in ThyroSeq v1.\u003c\/p\u003e\n\n\u003cp\u003eThis panel was expanded as ThyroSeq v2.1 and published in 2015 to include additional point mutations in EIF1AX and BRAF V601K and detection of over 40 other gene fusions including THADA, ALK, PAX8::PPARG, TRK1, and TRK3 genes. Finding BRAF mutations or PPARG, NTRK1, NTRK3, and ALK fusions were strong predictors of a higher risk of cancer—approaching 100%—while other mutations like RAS, PTEN, and EIF1AX or THADA fusions were associated with a significant but lower risk of cancer.\u003c\/p\u003e\n\n\u003cp\u003eThe latest platform of ThyroSeq v3 is currently commercially available. Other commercially available molecular platforms for preoperative diagnosis of indeterminate thyroid nodules include microRNA (miRNA) classifiers such as RosettaGX Reveal and mirTHYtype, or combined miRNA and somatic gene mutational platforms such as Asuragen.\u003c\/p\u003e\n\n\u003ch2 id=\"clinical\"\u003eMolecular Tests in Clinical Practice: How Testing Works\u003c\/h2\u003e\n\n\u003cp\u003eUnderstanding how molecular testing fits into the clinical workflow is important for patients. Thyroid FNAB procedures predominantly occur in outpatient clinics and are performed by a range of physicians including endocrinologists, radiologists, surgeons, and pathologists.\u003c\/p\u003e\n\n\u003cp\u003eWhen rapid on-site evaluation (ROSE) is available, adequacy and diagnosis can be made within a few minutes. In this scenario, additional needle passes for indeterminate nodules can be obtained and sent out for molecular testing to Afirma, ThyroSeq, or another desired platform. However, in settings where ROSE is unavailable, specimens are collected for subsequent cytologic and molecular evaluation. In the latter scenario, practices vary among institutions, but a \"collect on all\" protocol for possible molecular testing seems to be the most efficient for both patients and the laboratory, rather than requiring a return visit and re-biopsy for an indeterminate result.\u003c\/p\u003e\n\n\u003cp\u003eBoth Afirma and ThyroSeq provide a send-out service as a reflex to indeterminate thyroid nodule FNA. Fresh FNA samples are preferred for optimal and successful testing, but ThyroSeq also offers molecular testing for tissue scrapings from FNA slides and from paraffin-embedded tissue.\u003c\/p\u003e\n\n\u003cp\u003eMost FNABs are sent out, and most laboratories have a reflex for molecular testing for Bethesda III or IV results. When rapid on-site evaluation is available, samples can be sent directly for molecular testing. The workflow typically follows this pattern:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003eNodules classified as Bethesda III or IV (indeterminate) are sent for molecular testing for further classification\u003c\/li\u003e\n  \u003cli\u003eNodules of Bethesda V and VI (suspicious or malignant) can be tested for mutations that inform prognosis and treatment (such as TERT promoter or TP53 mutations)\u003c\/li\u003e\n  \u003cli\u003eMost FNABs are sent out, and most labs have a reflex for molecular testing for Bethesda III or IV\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003ch2 id=\"itn\"\u003eMolecular Tests for Indeterminate Thyroid Nodules\u003c\/h2\u003e\n\n\u003cp\u003eMolecular tests were initially performed on indeterminate thyroid nodules as a rule-out malignancy test in order to risk stratify for surgery based on the negative predictive value. The indications for these tests have evolved significantly over the past decade. Three highly utilized, commercially available and validated platforms for thyroid nodules in the United States are Afirma Genomic Sequencing Classifier (Afirma GSC)\/Afirma Xpression Atlas (XA), ThyGeNEXT\/ThyraMIR (MPTX), and ThyroSeq v3.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAfirma GSC and Xpression Atlas\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003eAfirma GSC uses whole transcriptome RNA analysis using next-generation sequencing combined with machine learning. Nodules evaluated by Afirma result in a benign or suspicious classification. Initially, samples sent to Afirma are tested for sufficient RNA. Samples are then tested against classifiers to detect parathyroid tissue, medullary thyroid carcinoma, BRAF p.V600E, CCDC6::RET, or NCOA4::RET. When all classifiers are negative, GSC analyzes more than 10,000 genes and classifies samples as GSC-B (benign) or GSC-S (suspicious).\u003c\/p\u003e\n\n\u003cp\u003eCompared with Afirma GEC, Afirma GSC has enhanced diagnostic accuracy for oncocytic thyroid neoplasms. Introduced in 2019 and updated in 2020, Afirma Xpression Atlas (XA) enumerates mutations in 593 genes, informing 905 variants and 235 fusions in suspicious Afirma GSC samples. It is extended to include Bethesda V and VI nodules.\u003c\/p\u003e\n\n\u003cp\u003eComparing Afirma XA testing with whole-transcriptome RNA, targeted RNA, and targeted DNA sequencing, Angel and colleagues reported mutations and gene fusions associated with thyroid nodules with high reproducibility and accuracy. Key findings included:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eBRAF p.V600E was predominantly present in Bethesda V\/VI FNA samples\u003c\/li\u003e\n  \u003cli\u003eNRAS and HRAS variants were primarily seen in Bethesda III\/IV FNA samples\u003c\/li\u003e\n  \u003cli\u003eIn addition to point mutations in BRAF and RAS genes, Afirma XA reported mutations in TSHR p.M453T and SPOP p.P94R—two mutations mostly associated with benign nodules\u003c\/li\u003e\n  \u003cli\u003eAfirma XA detected many fusions seen in thyroid neoplasms including PAX8::PPARG, ETV6::NTRK3, CCDC6::RET, NCOA4::RET, STRN::ALK, AGK::BRAF, SND1::BRAF, and RBPMS::NTRK3\u003c\/li\u003e\n  \u003cli\u003eFusion of PAX8::GLIS3 was also detected with Afirma XA, which is associated with hyalinizing trabecular tumor\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAfirma XA also provides information about inherited syndromes with increased likelihood of thyroid cancer, which can be valuable for patients and their families.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThyroSeq v3\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003eThyroSeq v3 is the latest version of the targeted next-generation sequencing panel. It analyzes 112 thyroid cancer-related genes, providing comprehensive coverage of the genetic alterations known to be important in thyroid neoplasia. This panel detects point mutations, insertions\/deletions, gene fusions, and copy number alterations, giving doctors a detailed picture of the genetic landscape of a nodule.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThyGeNEXT\/ThyraMIR (MPTX)\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003eThis platform combines next-generation sequencing of key genes (ALK, BRAF, GNAS, HRAS, KRAS, NRAS, PIK3CA, PTEN, RET, and TERT promoter genes) with mRNA fusion gene detection (ALK, BRAF, NTRK, PPARG, RET, PAX8, TBP, USP33, and THADA) and miRNA analysis (miR-21, 29, 31, 138, 139, 155, 146, 204, 222, 375, 551). The combination of DNA, RNA, and miRNA analysis provides a multi-layered approach to nodule classification.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eClinical Implications: What This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThe evolution of molecular testing has profound implications for patient care. For patients with indeterminate thyroid nodules, these tests provide critical information that helps guide management decisions. A benign molecular result can often spare a patient from unnecessary surgery, allowing for conservative monitoring instead. A suspicious result, particularly one showing high-risk mutations like BRAF V600E or TERT promoter mutations, can prompt more aggressive surgical intervention.\u003c\/p\u003e\n\n\u003cp\u003eFor patients with advanced or recurrent thyroid cancer, molecular testing has become essential for devising an individual therapeutic plan. The identification of specific genetic alterations can open the door to targeted therapies. For example:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eBRAF V600E mutations can be targeted with BRAF inhibitors\u003c\/li\u003e\n  \u003cli\u003eRET fusions and mutations can be targeted with selective RET inhibitors\u003c\/li\u003e\n  \u003cli\u003eNTRK fusions can be targeted with TRK inhibitors\u003c\/li\u003e\n  \u003cli\u003eALK fusions can be targeted with ALK inhibitors\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThese targeted therapies represent a paradigm shift from traditional treatments like chemotherapy and radiation, offering the potential for more effective treatment with fewer side effects. A subset of patients with advanced disease may benefit from neoadjuvant therapy—treatment given before surgery to shrink tumors and make them more operable.\u003c\/p\u003e\n\n\u003cp\u003eThe current (fifth edition) World Health Organization criteria categorizes thyroid tumors into follicular-derived neoplasms (benign, low-risk, and malignant), C-cell-derived carcinomas (medullary thyroid carcinoma), mixed medullary and follicular cell-derived carcinomas, and other rare non-follicular, non-C-cell-derived tumors including mucoepidermoid carcinoma, secretory carcinoma, sclerosing mucoepidermoid carcinoma with eosinophilia, cribriform morular thyroid carcinoma, and thyroblastoma. Specific genetic variants have been described in some of these rare primary tumors:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eCRTC1::MAML2 in mucoepidermoid carcinoma\u003c\/li\u003e\n  \u003cli\u003eETV6::NTRK3 in secretory carcinoma\u003c\/li\u003e\n  \u003cli\u003eAPC in cribriform morular thyroid carcinoma\u003c\/li\u003e\n  \u003cli\u003eDICER1 in thyroblastoma\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eSome of these genes are also aberrant in more common thyroid tumors, highlighting the interconnected nature of thyroid tumor genetics.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations of the Study\u003c\/h2\u003e\n\n\u003cp\u003eWhile this review provides a comprehensive overview of molecular diagnostics in thyroid pathology, several limitations should be acknowledged. First, most prevalence studies of genetic mutations were performed prior to a subset of PTC being reclassified into other categories such as non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), cribriform morular thyroid carcinoma, and well-differentiated tumor of uncertain malignant potential. This reclassification may affect the reported prevalence of certain mutations.\u003c\/p\u003e\n\n\u003cp\u003eSecond, the review focuses primarily on the two most common commercial platforms (Afirma and ThyroSeq), with less detailed discussion of other available tests. The relative performance of different platforms in head-to-head comparisons remains an area of ongoing research.\u003c\/p\u003e\n\n\u003cp\u003eThird, while molecular testing provides valuable risk stratification information, it cannot provide a definitive diagnosis in all cases. Some nodules with benign molecular results may still prove to be malignant upon surgical excision, and some with suspicious results may turn out to be benign. The positive predictive value and negative predictive value of these tests vary depending on the pretest probability of malignancy, which is influenced by nodule size, ultrasound features, and patient risk factors.\u003c\/p\u003e\n\n\u003cp\u003eFourth, the cost of molecular testing and insurance coverage can be barriers to access for some patients. The authors do not address the cost-effectiveness of these testing strategies in detail.\u003c\/p\u003e\n\n\u003cp\u003eFinally, the field is rapidly evolving. New genetic alterations are being discovered, and the clinical significance of some variants—particularly those of uncertain significance—remains unclear. As more data accumulate, our understanding of how to interpret and act on molecular results will continue to refine.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients\u003c\/h2\u003e\n\n\u003cp\u003eBased on this review, here are key recommendations for patients facing thyroid nodule evaluation:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUnderstand your Bethesda category.\u003c\/strong\u003e If you have had a fine needle aspiration biopsy, ask your doctor about your Bethesda category. Categories III and IV are considered indeterminate and are the primary candidates for molecular testing.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDiscuss molecular testing options.\u003c\/strong\u003e If your nodule is indeterminate, ask whether molecular testing is recommended. The three main platforms available in the United States are Afirma GSC\/XA, ThyroSeq v3, and ThyGeNEXT\/ThyraMIR. Each has its own strengths and limitations.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about the implications of results.\u003c\/strong\u003e A benign molecular result may allow you to avoid surgery and opt for active surveillance instead. A suspicious result may prompt surgery, and the specific genetic findings may influence the extent of surgery and follow-up.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eInquire about genetic testing for advanced disease.\u003c\/strong\u003e If you have advanced, recurrent, or aggressive thyroid cancer, molecular testing is essential for identifying potential targeted therapy options. Ask your oncologist about testing for BRAF, RET, NTRK, ALK, and other actionable mutations.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eConsider family implications.\u003c\/strong\u003e Some genetic alterations associated with thyroid cancer can be inherited. If you have a known genetic syndrome or a strong family history of thyroid cancer, genetic counseling may be appropriate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSeek care at a specialized center.\u003c\/strong\u003e Thyroid nodule management is complex and rapidly evolving. Centers with expertise in thyroid pathology and molecular diagnostics, like Massachusetts General Hospital, can provide the most up-to-date, personalized care.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eRemember that molecular testing is a tool to inform—not replace—clinical judgment. Your doctor will integrate molecular results with ultrasound features, nodule size, your clinical history, and other factors to develop a personalized management plan.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is an indeterminate thyroid nodule and why is it a problem?\u003c\/h3\u003e\n\u003cp\u003eAn indeterminate thyroid nodule is one where the biopsy cells look abnormal but doctors cannot tell if it is benign or malignant. This happens in up to 30% of fine needle aspiration biopsies. It creates a dilemma because doctors must decide between surgery or monitoring, and molecular testing helps make that decision.\u003c\/p\u003e\n\u003ch3\u003eHow does molecular testing help with indeterminate thyroid nodules?\u003c\/h3\u003e\n\u003cp\u003eMolecular testing analyzes the genetic material (DNA or RNA) of cells from a biopsy. It can help classify indeterminate nodules more accurately, predict cancer aggressiveness, and guide treatment. For example, a benign result may allow avoiding surgery, while a suspicious result may prompt surgery and influence its extent.\u003c\/p\u003e\n\u003ch3\u003eWhat are the main molecular tests available for thyroid nodules?\u003c\/h3\u003e\n\u003cp\u003eThe main commercially available platforms in the United States are Afirma GSC\/XA, ThyroSeq v3, and ThyGeNEXT\/ThyraMIR. Afirma uses whole transcriptome RNA analysis, ThyroSeq analyzes 112 thyroid cancer-related genes, and ThyGeNEXT\/ThyraMIR combines DNA, RNA, and miRNA analysis. Each has its own strengths and limitations.\u003c\/p\u003e\n\u003ch3\u003eWhat does a benign molecular test result mean for me?\u003c\/h3\u003e\n\u003cp\u003eA benign molecular result on an indeterminate nodule often means you can avoid surgery and instead choose active surveillance, which involves regular monitoring. However, it is not a guarantee, as some nodules with benign results may still be malignant upon surgical removal. Your doctor will integrate this with other factors.\u003c\/p\u003e\n\u003ch3\u003eWhat does a suspicious molecular test result mean?\u003c\/h3\u003e\n\u003cp\u003eA suspicious result, especially with high-risk mutations like BRAF V600E or TERT promoter, may prompt surgery. The specific genetic findings can influence the extent of surgery and follow-up. It does not definitively mean cancer, as some suspicious results turn out to be benign, but it indicates a higher risk.\u003c\/p\u003e\n\u003ch3\u003eCan molecular testing help if I have advanced thyroid cancer?\u003c\/h3\u003e\n\u003cp\u003eYes, for advanced, recurrent, or aggressive thyroid cancer, molecular testing is essential to identify potential targeted therapy options. It can detect mutations or fusions in genes like BRAF, RET, NTRK, and ALK, which can be treated with specific inhibitors. This offers a more personalized approach than traditional treatments.\u003c\/p\u003e\n\u003ch3\u003eAre there any limitations to molecular testing?\u003c\/h3\u003e\n\u003cp\u003eYes, molecular testing cannot provide a definitive diagnosis in all cases. Some benign results may still be malignant, and some suspicious results may be benign. The accuracy depends on pretest probability, and cost or insurance coverage can be barriers. The field is rapidly evolving, and some variants are of uncertain significance.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal Article:\u003c\/strong\u003e \"Update on Molecular Diagnostics in Thyroid Pathology: A Review\"\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Bayan Alzumaili and Peter M. Sadow\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAffiliation:\u003c\/strong\u003e Departments of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e Genes, 2023, Volume 14, Issue 7, Article 1314\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e 10.3390\/genes14071314\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePublication Date:\u003c\/strong\u003e Published June 22, 2023 (Received May 31, 2023; Revised June 13, 2023; Accepted June 19, 2023)\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCorresponding Author:\u003c\/strong\u003e Peter M. Sadow, MD, PhD (psadow@mgh.harvard.edu)\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research published in an open-access journal under the Creative Commons Attribution (CC BY) license. The original article can be accessed through the DOI link provided above.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47377200709788,"sku":null,"price":0.0,"currency_code":"CHF","in_stock":true}],"url":"https:\/\/diagnosticdetectives.ch\/it\/products\/understanding-molecular-diagnostics-in-thyroid-pathology-a-patients-guide-to-genetic-testing-for-thyroid-nodules","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}